Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 699

1.

Non-Ischemic or Ischemic Laparoscopic Partial Nephrectomy Using a Newly Developed Hybrid Energy Device in a Porcine Model.

Tanaka M, Irie S, Nakagawa K, Nishimatsu H, Inokuchi J, Eto M.

J Endourol. 2019 Sep 11. doi: 10.1089/end.2019.0435. [Epub ahead of print]

PMID:
31507214
2.

Berezinskii-Kosterlitz-Thouless Transition of Two-Component Bose Mixtures with Intercomponent Josephson Coupling.

Kobayashi M, Eto M, Nitta M.

Phys Rev Lett. 2019 Aug 16;123(7):075303. doi: 10.1103/PhysRevLett.123.075303.

PMID:
31491091
3.

Contractile elements and their sympathetic regulations in the pig urinary bladder: a species and regional comparative study.

Mitsui R, Lee K, Uchiyama A, Hayakawa S, Kinoshita F, Kajioka S, Eto M, Hashitani H.

Cell Tissue Res. 2019 Aug 24. doi: 10.1007/s00441-019-03088-6. [Epub ahead of print]

PMID:
31446446
4.

Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Anticancer Res. 2019 Aug;39(8):4411-4414. doi: 10.21873/anticanres.13612.

PMID:
31366538
5.

Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.

Akitake M, Yamaguchi A, Shiota M, Imada K, Tatsugami K, Yokomizo A, Naito S, Eto M.

Anticancer Res. 2019 Aug;39(8):4325-4328. doi: 10.21873/anticanres.13598.

PMID:
31366524
6.

Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid β fibrils.

Eto M, Hashimoto T, Shimizu T, Iwatsubo T.

PLoS One. 2019 Jul 10;14(7):e0219465. doi: 10.1371/journal.pone.0219465. eCollection 2019.

7.

Contribution of short-term global clinical health experience to the leadership competency of health professionals: a qualitative study.

Hayashi M, Son D, Onishi H, Eto M.

BMJ Open. 2019 Jul 3;9(7):e027969. doi: 10.1136/bmjopen-2018-027969.

8.

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.

Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; JCOG UOSG.

J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422. [Epub ahead of print]

PMID:
31251717
9.

Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer.

Kashiwagi E, Imada K, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M.

Andrologia. 2019 Oct;51(9):e13354. doi: 10.1111/and.13354. Epub 2019 Jun 23.

PMID:
31230398
10.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G.

Int J Clin Oncol. 2019 Sep;24(9):1089-1098. doi: 10.1007/s10147-019-01450-w. Epub 2019 Jun 19.

PMID:
31218529
11.

The Role of Nuclear Receptors in Prostate Cancer.

Shiota M, Fujimoto N, Kashiwagi E, Eto M.

Cells. 2019 Jun 17;8(6). pii: E602. doi: 10.3390/cells8060602. Review.

12.

Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.

Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M.

Urol Oncol. 2019 Jun 12. pii: S1078-1439(19)30153-X. doi: 10.1016/j.urolonc.2019.04.020. [Epub ahead of print]

PMID:
31202731
13.

Papillary renal cell carcinoma with massive hematoma mimicking hemangioma.

Hiraki Y, Okamoto D, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Fujita N, Eto M, Kinoshita F, Honda H.

Radiol Case Rep. 2019 Jun 6;14(8):1003-1006. doi: 10.1016/j.radcr.2019.05.025. eCollection 2019 Aug.

14.

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.

Inokuchi J, Eto M.

Cancer Manag Res. 2019 May 15;11:4519-4528. doi: 10.2147/CMAR.S167708. eCollection 2019. Review.

15.

Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer.

Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M.

Anticancer Res. 2019 Jun;39(6):3191-3195. doi: 10.21873/anticanres.13457.

PMID:
31177166
16.

Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy.

Kobayashi S, Cho B, Huaulmé A, Tatsugami K, Honda H, Jannin P, Hashizumea M, Eto M.

Int J Comput Assist Radiol Surg. 2019 Aug;14(8):1449-1459. doi: 10.1007/s11548-019-01980-8. Epub 2019 May 22.

PMID:
31119486
17.

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Cancer Chemother Pharmacol. 2019 Sep;84(3):561-566. doi: 10.1007/s00280-019-03874-7. Epub 2019 May 21.

PMID:
31115605
18.

Low-Intensity Exercise Suppresses CCAAT/Enhancer-Binding Protein δ/Myostatin Pathway Through Androgen Receptor in Muscle Cells.

Son BK, Eto M, Oura M, Ishida Y, Taniguchi S, Ito K, Umeda-Kameyama Y, Kojima T, Akishita M.

Gerontology. 2019;65(4):397-406. doi: 10.1159/000499826. Epub 2019 May 16.

PMID:
31096217
19.

Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.

Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M.

Prostate. 2019 Jul;79(10):1147-1155. doi: 10.1002/pros.23828. Epub 2019 May 11.

PMID:
31077419
20.

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H.

Clin Cancer Res. 2019 Aug 1;25(15):4808-4819. doi: 10.1158/1078-0432.CCR-18-3991. Epub 2019 May 10.

PMID:
31076547
21.

TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.

Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM.

Mol Cancer Res. 2019 Aug;17(8):1613-1626. doi: 10.1158/1541-7786.MCR-18-1235. Epub 2019 May 1.

PMID:
31043488
22.

Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.

Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M.

Clin Genitourin Cancer. 2019 Jun;17(3):e387-e393. doi: 10.1016/j.clgc.2019.03.021. Epub 2019 Apr 6.

PMID:
31036465
23.

MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.

Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y.

Cancer Sci. 2019 Jun;110(6):1897-1908. doi: 10.1111/cas.14026. Epub 2019 May 24.

24.

Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program.

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M.

Jpn J Clin Oncol. 2019 Apr 12. pii: hyz054. doi: 10.1093/jjco/hyz054. [Epub ahead of print]

PMID:
30977820
25.

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer.

Cancer Sci. 2019 Jun;110(6):1820-1828. doi: 10.1111/cas.14019. Epub 2019 May 13.

26.

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H.

Jpn J Clin Oncol. 2019 Jun 1;49(6):506-514. doi: 10.1093/jjco/hyz026.

PMID:
30941424
27.

The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.

Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M.

Cancer Chemother Pharmacol. 2019 May;83(5):933-938. doi: 10.1007/s00280-019-03811-8. Epub 2019 Mar 13.

PMID:
30868236
28.

Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.

Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M.

Med Oncol. 2019 Feb 28;36(4):32. doi: 10.1007/s12032-019-1257-1.

PMID:
30815799
29.

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.

Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.

JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.

30.

[Ⅱ. How Has the Treatment Outcomes for Advanced Renal Cell Carcinoma Improved in the 10 Years after Approval of Targeted Therapy ?]

Imada K, Eto M.

Gan To Kagaku Ryoho. 2019 Jan;46(1):40-44. Japanese. No abstract available.

PMID:
30765640
31.

Overview of current and future systemic therapy for metastatic renal cell carcinoma.

Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H.

Jpn J Clin Oncol. 2019 May 1;49(5):395-403. doi: 10.1093/jjco/hyz013. Review.

PMID:
30722031
32.

Reconstitution of the embryonic kidney identifies a donor cell contribution to the renal vasculature upon transplantation.

Murakami Y, Naganuma H, Tanigawa S, Fujimori T, Eto M, Nishinakamura R.

Sci Rep. 2019 Feb 4;9(1):1172. doi: 10.1038/s41598-018-37793-z.

33.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

34.

Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle.

Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, Eto M.

Low Urin Tract Symptoms. 2019 Apr;11(2):O209-O217. doi: 10.1111/luts.12247. Epub 2019 Jan 10.

PMID:
30632283
35.

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy.

Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M.

Front Oncol. 2018 Dec 18;8:635. doi: 10.3389/fonc.2018.00635. eCollection 2018.

36.

Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor.

Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y.

J Cancer. 2018 Oct 31;9(23):4440-4448. doi: 10.7150/jca.25279. eCollection 2018.

37.

Competencies required for general practitioners/family physicians in urban areas versus non-urban areas: a preliminary study.

Mitsuyama T, Son D, Eto M.

BMC Fam Pract. 2018 Nov 29;19(1):186. doi: 10.1186/s12875-018-0869-4.

38.

Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study).

Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, Hirakawa A, Toba K; Strawberry study investigators.

BMJ Open. 2018 Nov 25;8(11):e021759. doi: 10.1136/bmjopen-2018-021759.

39.

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.

Shiota M, Namitome R, Kobayashi T, Inokuchi J, Tatsugami K, Eto M.

Int J Urol. 2019 Mar;26(3):426-428. doi: 10.1111/iju.13870. Epub 2018 Nov 21. No abstract available.

PMID:
30461081
40.

Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.

Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M.

Urol Oncol. 2019 Mar;37(3):180.e19-180.e24. doi: 10.1016/j.urolonc.2018.10.020. Epub 2018 Nov 13.

PMID:
30446464
41.

RSK2 contributes to myogenic vasoconstriction of resistance arteries by activating smooth muscle myosin and the Na+/H+ exchanger.

Artamonov MV, Sonkusare SK, Good ME, Momotani K, Eto M, Isakson BE, Le TH, Cope EL, Derewenda ZS, Derewenda U, Somlyo AV.

Sci Signal. 2018 Oct 30;11(554). pii: eaar3924. doi: 10.1126/scisignal.aar3924.

42.

Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.

Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K.

Cancer Immunol Immunother. 2019 Feb;68(2):201-211. doi: 10.1007/s00262-018-2263-4. Epub 2018 Oct 24.

PMID:
30357491
43.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI.

Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.

44.

Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.

Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H.

Int J Urol. 2019 Feb;26(2):202-210. doi: 10.1111/iju.13830. Epub 2018 Oct 21.

PMID:
30345560
45.

Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy.

Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M.

Mol Clin Oncol. 2018 Nov;9(5):575-581. doi: 10.3892/mco.2018.1718. Epub 2018 Sep 13.

46.

The Evaluation of Laparoscopic Surgery on Pregnant Patients with Ovarian Cysts and Its Effects on Pregnancy over the Past 5 Years.

Kurihara K, Minagawa M, Masuda M, Fukuyama M, Tanigaki K, Yamamoto A, Kato S, Fujita H, Eto M.

Gynecol Minim Invasive Ther. 2018 Jan-Mar;7(1):1-5. doi: 10.4103/GMIT.GMIT_12_17. Epub 2018 Feb 16.

47.

Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T.

Clin Genitourin Cancer. 2018 Dec;16(6):e1201-e1214. doi: 10.1016/j.clgc.2018.07.028. Epub 2018 Aug 11.

PMID:
30224330
48.

Light Controlled Optical Aharonov-Bohm Oscillations in a Single Quantum Ring.

Kim H, Park S, Okuyama R, Kyhm K, Eto M, Taylor RA, Nogues G, Dang LS, Potemski M, Je K, Kim J, Kyhm J, Song J.

Nano Lett. 2018 Oct 10;18(10):6188-6194. doi: 10.1021/acs.nanolett.8b02131. Epub 2018 Sep 20.

PMID:
30223652
49.

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone.

Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M.

Prostate Int. 2018 Sep;6(3):104-109. doi: 10.1016/j.prnil.2017.10.002. Epub 2017 Nov 21.

50.

Surgical as Opposed to Transcatheter Aortic Valve Replacement Improves Basal Interventricular Septal Hypertrophy.

Yoshitani H, Isotani A, Song JK, Shirai S, Umeda H, Jang JY, Onoue T, Toki M, Sun BJ, Kim DH, Kagiyama N, Hayashida A, Song JM, Eto M, Nishimura Y, Ando K, Hanyu M, Yoshida K, Levine RA, Otsuji Y.

Circ J. 2018 Oct 25;82(11):2887-2895. doi: 10.1253/circj.CJ-18-0390. Epub 2018 Aug 22.

Supplemental Content

Support Center